BOTHELL, Wash., and ELMWOOD PARK, N.J., Dec. 14 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc. , a developer of bioactive peptides, and Grant Industries, a privately held developer, manufacturer and marketer of cosmetic, textile, and performance specialty chemicals, today announced that they have entered into a marketing partnership to supply innovative ingredients to the personal care industry through application of Helix BioMedix's patented peptide technology.
Under license from Helix BioMedix, Grant has developed and validated peptide-based and peptide-enhanced ingredient blends for skin care applications targeting improvement in the appearance of acne-prone skin or reduction of visible signs of aging such as lines, wrinkles and loss of firmness and elasticity. The license agreement is the culmination of a collaborative venture to bring advanced skin care science to more consumers by leveraging the respective strengths of each organization.
Paul Granatell, Executive Director of Grant Industries, commented, "We have high expectations that our partnership with Helix BioMedix will provide our customer companies with a significant edge in the highly competitive cosmeceutical skin care market. We've already invested substantial resources targeting the development and validation of new cosmetic ingredients based on Helix BioMedix's peptides in anticipation of the completion of this license negotiation."
R. Stephen Beatty, President and Chief Executive Officer of Helix BioMedix, added, "We are delighted with the cosmetics industry know-how that Grant Industries has brought to this partnership. As a technology-focused company, Helix BioMedix's expertise is in the identification and validation of new peptides for cosmetic application. However, in the cosmetics and personal care arena, a critical component of success is the ultimate ability to apply the technology to build a final product that is efficacious, safe and cosmetically elegant. Grant's expertise in technology application is the perfect complement to Helix's expertise in technology development."
Initial products developed through the partnership on behalf of cosmetic and personal care industry manufacturers and marketers are expected to launch in the first half of 2007.
About Grant Industries
Grant Industries is a privately held company, located in Elmwood Park, NJ, involved in the research, development, manufacturing, and marketing of cosmetic, textile, and performance specialty chemicals. The company's involvement in the textile industry dates back 60 years and four generations. Grant offers the cosmetic industry a diversified product line of Gransil silicone elastomer gels and powders, specialty materials and formulated products. The company maintains manufacturing and warehousing in Elmwood Park, NJ, Mexico, Dominican Republic, England, Korea, Japan, China, South Africa and the European Union. More information about the company can be found on the company's website at www.grantinc.com.
About Helix BioMedix
Helix BioMedix, Inc. is a biopharmaceutical company that has a portfolio of issued patents that covers six distinct classes of peptides, covering over 100,000 unique peptide sequences. The company's mission is to become the industry leader in developing and commercializing small proteins known as bioactive peptides. The antimicrobial and wound healing properties of these peptides qualify them for inclusion in a wide range of both pharmaceutical and consumer products. The company is currently focused on the development of selected peptides as topical anti-infectives and in wound healing. Non- pharmaceutical applications being pursued by Helix BioMedix include adjuvants for cosmetics/cosmeceuticals, personal care, plant health, animal health and wide-spectrum biocides. More information about the company and its proprietary peptides can be found on the company's website at www.helixbiomedix.com.
Important Notice
This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that Helix BioMedix, Inc. (the "company" or "our") expects, believes or anticipates may occur in the future, including statements related to our potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in our reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.
Contact: Investor Relations: Helix BioMedix, Inc. Cameron Associates David H. Kirske, Alison Ziegler, 212-554-5469 425-402-8400 alison@cameronassoc.comdkirske@helixbiomedix.com or: Grant Industries, Inc. Paul Granatell, 201-791-8700 pgranatell@grantinc.com
Helix BioMedix, Inc.CONTACT: David H. Kirske of Helix BioMedix, Inc., +1-425-402-8400,dkirske@helixbiomedix.com; or Paul Granatell of Grant Industries, Inc.,+1-201-791-8700, pgranatell@grantinc.com; or Investor Relations, AlisonZiegler of Cameron Associates, +1-212-554-5469, alison@cameronassoc.com
